AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta)... Show more
AbbVie has largely completed the difficult transition away from Humira, which lost U.S. exclusivity in 2023 and continues to decline in the face of biosimilar competition. The company's medium-term positioning now rests on two immunology franchises with durable momentum. Skyrizi captured about half of new patient starts in inflammatory bowel disease (IBD), while Rinvoq is expanding into dermatology and rheumatology indications. Together, these products accounted for more than 47% of total revenue by mid-2026, and management expects combined sales above $31 billion this year.
The company is also laying the groundwork for its next immunology cycle. The roughly $10.9 billion acquisition of Apogee Therapeutics added zumilokibart, a late-stage anti-IL-13 (interleukin-13) antibody targeting atopic dermatitis, positioning AbbVie to compete with the category-leading Dupixent. Beyond immunology, a growing neuroscience portfolio led by Vraylar, Ubrelvy, Qulipta, and the newly approved Parkinson's therapy Juvmo provides diversification, with management guiding the Parkinson's franchise toward more than $5 billion in peak sales.
Several regulatory and clinical milestones could reshape investor expectations over the next several quarters. The FDA is reviewing Rinvoq for vitiligo and alopecia areata, with a U.S. decision on vitiligo expected later in 2026 and on alopecia areata in early 2027; management estimates the two dermatology indications could add nearly $2 billion in combined peak sales. A subcutaneous induction approval for Skyrizi in Crohn's disease is also anticipated, improving convenience and potentially accelerating patient-share gains in 2027.
In the pipeline, Phase 3 readouts for Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus, along with lutikizumab data in HS, represent the next wave of label expansion. In oncology, positive Phase 3 results for etentamig in multiple myeloma have supported a U.S. regulatory submission, with a decision expected in 2027. Analyst ratings have trended more optimistic, with firms such as Morgan Stanley, Wells Fargo, and Leerink Partners raising price targets in recent months, reflecting growing confidence in the growth trajectory.
AbbVie's trajectory is shaped by a mix of secular demand and policy-driven pricing pressure. Immunology markets for conditions such as atopic dermatitis and asthma are growing 15% to 20% annually, providing a favorable demand backdrop. At the same time, the Inflation Reduction Act's Medicare drug-price negotiation framework introduces a structural pricing headwind, with management highlighting Vraylar pricing changes as a 2027 impact and an ongoing dispute over Botox's eligibility for negotiation.
Interest rates and inflation affect AbbVie primarily through capital-allocation and valuation channels rather than direct demand, given the relatively inelastic nature of many specialty pharmaceuticals. However, the aesthetics segment, which has seen softer dermal filler demand, remains more exposed to discretionary consumer spending cycles. Geopolitical and supply-chain considerations are modest for a U.S.-centric specialty portfolio, though foreign-exchange movements can influence reported revenue.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, exchange-traded fund (ETF), or other asset may move bullish, bearish, or sideways over the coming week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments. The platform also offers searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking AbbVie's evolving outlook, tools like this can add a data-driven layer to traditional fundamental analysis.
Looking toward 2026 and beyond, AbbVie's guidance for approximately $67.8 billion in full-year revenue and adjusted earnings of $13.95 to $13.99 per share reflects continued double-digit growth from Skyrizi and Rinvoq. Management has pointed to high-single-digit compound annual revenue growth through 2029, supported by a pipeline with no major loss-of-exclusivity events expected to materially disrupt the business this decade.
Longer-term, investors will watch whether combination immunology regimens built around Skyrizi with ABBV-382 and ABBV-701 can deliver best-in-class, durable remission in IBD, and whether the oncology pipeline—including etentamig and Epkinly—can scale into meaningful revenue contributors. Capital allocation priorities remain balanced, with a 5.2% dividend increase to $1.82 per share and a focus on bolt-on acquisitions in immunology, neuroscience, oncology, and obesity. Consensus analyst expectations, with an average price target near $310, suggest the market broadly anticipates continued execution, though regulatory outcomes and competitive dynamics remain key variables to monitor.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.94% | ||
| NVS - ABBV | 52% Loosely correlated | -0.50% | ||
| BMY - ABBV | 51% Loosely correlated | +0.79% | ||
| JNJ - ABBV | 51% Loosely correlated | +1.25% | ||
| AMGN - ABBV | 49% Loosely correlated | -0.15% | ||
| GILD - ABBV | 47% Loosely correlated | -0.06% | ||
More | ||||
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
ABBV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 27 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 57%.
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 18 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABBV as a result. In 36 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +0.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 222 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 217 of 349 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.421). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.700). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.